People · Operator
Named in public records as an officer, director or promoter · active 2021–2021 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Clarus Therapeutics Holdings, Inc. | — | Pharmaceuticals | Series B | $15.0M | $289.4M | 2021 |
Mark A. Prygocki at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mark A. Prygocki on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Joseph Kenneth Hernandez | 1 | 1 |
| Elizabeth A. Cermak | 1 | 1 |
| Alex A. Zisson | 1 | 1 |
| John Kenneth Amory | 1 | 1 |
| Robert E. Dudley | 1 | 1 |
| Richard E. Peterson | 1 | 1 |
| Frank Kenneth Jaeger | 1 | 1 |
| Steven A. Bourne | 1 | 1 |
| Kimberly Kenneth Murphy | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.